Please login to the form below

Not currently logged in
Email:
Password:

Morphotek

This page shows the latest Morphotek news and features for those working in and with pharma, biotech and healthcare.

Late-stage ovarian cancer

Late-stage ovarian cancer

Menarini Biotech's abagovomab and Morphotek/ Eisai's farletuzumab have both had disappointing results in late-stage clinical trials.

Latest news

  • Eisai's farletuzumab fails ovarian cancer trial Eisai's farletuzumab fails ovarian cancer trial

    Morphotek remains committed to research to understand the potential role of farletuzumab in ovarian and other types of cancer.". ... Eisai acquired Morphotek in 2007 in a $325m deal designed to bring in a portfolio of oncology drug candidates.

  • Eisai subsidiary in tie up for prostate cancer antibodies

    Morphotek will apply its proprietary Morphodoma antibody technology to the development of novel therapeutic antibodies for use in the treatment of prostate cancer. ... The agreement between NCI and Morphotek is part of an existing collaborative

  • Eisai acquires MGI Pharma for USD 3.9bn

    In 2006, Eisai bought four cancer drugs from Ligand Pharmaceuticals for a total of USD 205m, while in early 2007 the company spent USD 325m on the buy up of Morphotek.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    68. Sorrento Therapeutics / Morphotek. Research and option agreement. To generate chemotherapeutic antibody drug conjugates (ADCs) (platform).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics